Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zaltrap and docetaxel in recurrent ovarian, primary peritoneal, and fallopian tube cancer
NCT00436501Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Mar 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in ovarian epithelial cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Started Jan 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00436501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436501.